Nintedanib
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Nintedanib: From Idiopathic Pulmonary Fibrosis to Dermatofibrosarcoma Protuberans
Note on data provenance: The evidence pack does not include sourced original-indication or MOA data (
original_indications: [],original_moa: "[Data Gap]", flagged as DG001/DG002). The original indication cited here (idiopathic pulmonary fibrosis) reflects nintedanib's well-established public drug classification and requires confirmation against a primary source (DrugBank/Fimea label) before use in a formal safety review.
One-Sentence Summary
Nintedanib is a multi-target tyrosine kinase inhibitor generally known for its use in fibrotic lung disease. The TxGNN model predicts it may be effective for dermatofibrosarcoma protuberans, but this direction is currently supported by only 1 mechanism-related publication and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in current evidence pack (blocking data gap — see DG001) |
| Predicted New Indication | Dermatofibrosarcoma protuberans |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L4 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for nintedanib is not available in this evidence pack (DG002). Based on generally known pharmacology, nintedanib is a triple angiokinase inhibitor targeting VEGFR, FGFR, and PDGFR, and its efficacy in fibrotic lung disease has been established in the broader literature — but this has not been confirmed against a sourced document in this pack.
The single supporting publication (PMID 29408302) is a pharmacological review of small-molecule PDGFR inhibitors in neoplastic disease. Dermatofibrosarcoma protuberans is a tumour characteristically driven by a COL1A1–PDGFB gene fusion, which causes constitutive PDGFR pathway activation. If nintedanib's PDGFR-inhibitory activity is confirmed, there is a plausible mechanistic rationale for activity in PDGFR-driven sarcomas such as DFSP and liposarcoma — consistent with all three of TxGNN's top-ranked predictions being soft-tissue sarcomas.
This mechanistic link is presently supported by class-level literature only, not by drug-specific or disease-specific studies, and should be treated as hypothesis-generating rather than confirmatory.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological Research | Reviews small-molecule PDGFR inhibitors in neoplastic disease; describes the PDGF/PDGFR signalling axis relevant to PDGFR-driven tumours such as DFSP, supporting a class-level mechanistic rationale rather than drug-specific efficacy data |
Finland Market Information
Nintedanib is not currently marketed in Finland; no authorization records are available in the evidence pack (total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a single class-level mechanism review with no drug-specific or disease-specific clinical or preclinical data, no registered trials for any of the three predicted sarcoma indications, and no Finland market presence to draw on for real-world safety experience. The blocking data gap (DG001 — TFDA/Fimea package insert warnings and contraindications) also prevents entry into the S1 safety pre-screening stage.
To proceed, the following is needed:
- TFDA/Fimea package insert data (warnings, contraindications) to resolve DG001 and unblock S1 safety pre-screening
- Confirmed original indication and MOA from DrugBank or the approved label (DG002)
- Drug-specific preclinical or case-level evidence (e.g., PDGFR-inhibitor activity confirmed for nintedanib in DFSP or liposarcoma models)
- Continued literature/trial monitoring, as liposarcoma and ovarian myxoid liposarcoma currently have zero supporting evidence beyond the TxGNN score
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.